TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03214484

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: By comparing the evolution of the visual acuity curves.
Description: By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: By comparing the evolution of the visual acuity curves.
Description: By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: By comparing the evolution of the curves.
Description: By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: By comparing the evolution of the curves.
Description: By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.
Study: NCT01355705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: 40, 60, or 80 mg/m2 intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 15 mg daily by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg weekly by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81 or 325 mg daily by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg subcutaneous on Day 2
Study: NCT03567070

Intervention type: OTHER
Group type: OTHER
Intervention: qualitative study based on an individual clinical interview
Description: qualitative study based on an individual clinical interview
Study: NCT02520089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma plus bone autograft
Description: Sample of 40 mL of peripheric blood and processed to obtain 5 mL of platelet rich plasma, and collocated into pseudoarthrosis
Study: NCT01765010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Study: NCT02011165

Intervention type: PROCEDURE
Intervention: Positioning measuring device
Description: A tennis ball in the night shirt will prevent supine position during sleep.
Study: NCT01765010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01614132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maintenance chemotherapy (vincristin, cisplatin and CCNU)
Description: maintenance chemotherapy of maximum of 8 cycles á 42 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy of the partial brain
Study: NCT03068091

Intervention type: DEVICE
Group type: OTHER
Intervention: Chest CT
Description: Inspiration and expiration chest CT

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pulmonary Function Testing
Description: Measure lung function
Study: NCT02971878

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)
Description: Human embryos will be cultured in media that contains 3 antioxidants (Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)) that can be found in the in vivo Environment.
Study: NCT03400605

Intervention type: OTHER
Intervention: Infant feeding questionnaire
Description: Prospective infant feeding questionnaire administered over the telephone or in-person at 2 weeks and at 2, 4 and 6 months postpartum
Study: NCT03594240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM)
Description: Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM) once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in placebo group received placebo that were similar in appearance to Vitamin B complex tablets and the administered dose was as the same schedule as Vitamin B complex.
Study: NCT04529356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: By using different frequency of TMS, the device can generate different effects. For low frequency, such as 1HZ, it mainly generates inhibition on the brain cortex; while high frequency (usually higher than 10HZ) can generate stimulation effects. The later one could be used to treat different central nervous disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: By using different frequency of TMS, the device can generate different effects. For low frequency, such as 1HZ, it mainly generates inhibition on the brain cortex; while high frequency (usually higher than 10HZ) can generate stimulation effects. The later one could be used to treat different central nervous disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen is used as the painkiller to alleviate patients' headache before and during the clinical trial. In order to decrease the medication bias, we required these patients to only use acetaminophen instead of other non-steroid anti-inflammatory drugs. In the meantime, participants are requested to recorder the frequency and dosage of acetaminophen they used during the treatment course.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen is used as the painkiller to alleviate patients' headache before and during the clinical trial. In order to decrease the medication bias, we required these patients to only use acetaminophen instead of other non-steroid anti-inflammatory drugs. In the meantime, participants are requested to recorder the frequency and dosage of acetaminophen they used during the treatment course.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen is used as the painkiller to alleviate patients' headache before and during the clinical trial. In order to decrease the medication bias, we required these patients to only use acetaminophen instead of other non-steroid anti-inflammatory drugs. In the meantime, participants are requested to recorder the frequency and dosage of acetaminophen they used during the treatment course.
Study: NCT02351427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: In one group, investigators administer bortezomib and steroid to manage acute cellular rejection in kidney transplantation, and compare the results with another group in which only steroid was administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid
Description: Investigators administer steroid in both groups for conventional treatment of acute cellular rejection.
Study: NCT01207271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: 16 sessions of cognitive therapy administered weekly by a community mental health therapist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive-Expressive Psychodynamic Therapy
Description: 16 sessions of supportive-expressive psychodynamic therapy administered weekly by a community mental health therapist
Study: NCT01639833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veriset Hemostatic Patch
Description: Topical hemostat

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TachoSil®
Description: Topical Hemostat
Study: NCT04397705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Status Engine
Description: Wearable sensors
Study: NCT03439709

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gamma knife radiosurgery
Description: Minimum 25 Gy of marginal dose is applied for residual tumor or resection cavity. Depending on the size of tumor, the dose can be varied.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanreotide 60Mg Solution for Injection
Description: Lanreotide injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide 60Mg Solution for Injection
Description: Lanreotide injection.
Study: NCT04516473

Intervention type: PROCEDURE
Intervention: Abdominal Body Contouring
Description: These are surgeries that correct for excess skin and its adverse consequences. The surgeries that focus on central area to remove a large hanging pannus is usually called panniculectomies or abdominoplasties; the former is focused on the excision of excess tissue to relieve impairment while the latter is generally considered a cosmetic surgery. The form of the surgery is case dependent and can range from removing apron of skin to complete contouring of the abdomen with tightening of the abdominal muscle and moving the belly button.
Study: NCT03033745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IgPro20
Description: A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IgPro20
Description: A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IgPro20
Description: A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.
Study: NCT01238939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK012 and 5-FU
Description: NK012 infusion on Day 1 of each 28 day cycle 5-FU continuous infusion on Days 1 and 15 of each 28 day cycle
Study: NCT00343512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel 75 mg/m2 IV (1-hour infusion) on day 1 of each cycle (cycle = 2 weeks) x 4 cycles

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: protein expression analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: neoadjuvant therapy
Study: NCT02755194

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. The exposure of interest includes taking specific prescribed medications during breastfeeding.
Study: NCT02738658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent
Study: NCT01499017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874 or placebo
Description: PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 3 mg to 100 mg. Correspondingly, placebo doses will be administered as suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874 or Placebo
Description: PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 300 mg to 650 mg. Correspondingly, placebo doses will be administered as suspension.
Study: NCT01114529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Early CNI to everolimus conversion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf or Neoral
Description: Active CNI-based control (Prograf or Neoral)
Study: NCT02678715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solubrux®
Description: prefabricated device adaptable by temperature

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solubrux®
Description: prefabricated device adaptable by temperature

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solubrux®
Description: prefabricated device adaptable by temperature

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solubrux®
Description: prefabricated device adaptable by temperature

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solubrux®
Description: prefabricated device adaptable by temperature

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solubrux®
Description: prefabricated device adaptable by temperature

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized Appliance
Description: customized device fabricated in the dental laboratory

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized Appliance
Description: customized device fabricated in the dental laboratory

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized Appliance
Description: customized device fabricated in the dental laboratory

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized Appliance
Description: customized device fabricated in the dental laboratory

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized Appliance
Description: customized device fabricated in the dental laboratory

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized Appliance
Description: customized device fabricated in the dental laboratory

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatics®
Description: standard device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatics®
Description: standard device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatics®
Description: standard device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatics®
Description: standard device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatics®
Description: standard device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatics®
Description: standard device
Study: NCT03979157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral Optoacoustic Tomography
Description: Non-invasive transcutaneous imaging of subcellular muscle components
Study: NCT02889458

Intervention type: OTHER
Intervention: Not Provided

Intervention type: OTHER
Intervention: Not Provided
Study: NCT02103868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Doing group and personal counseling for tobacco cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Doing group and personal counseling for tobacco cessation
Study: NCT01055002

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood stage parasite (BSP) inoculum
Description: Inoculum of human red blood cells infected with falciparum malaria administered intravenously on Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood stage parasite (BSP) inoculum
Description: Inoculum of human red blood cells infected with falciparum malaria administered intravenously on Day 1
Study: NCT02614079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DSSEP
Description: Collision testing after the placement of SCS leads
Study: NCT01699087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Description: In this corneal surgical procedure, the outer corneal epithelial layer will be removed, after which the corneal stroma will be reshaped by excimer laser ablation to reduce or eliminate refractive errors.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALLEGRETTO WAVE EYE-Q excimer laser system
Description: The ALLEGRETTO WAVE EYE-Q excimer laser system is used for corneal stroma reshaping during PRK surgery
Study: NCT03729947

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subfascial closed suction drain
Description: Ch 14 closed suction drain

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Subfascial closed suction drain
Description: Ch 14 closed suction drain
Study: NCT02499029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: NAC pills were administered each week. NAC is a N acetyl pro-drug of the naturally-occurring amino acid cystine. NAC is a white, crystalline powder with the molecular formula C5H9NO3S and with a molecular weight of 163.2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical looking placebo pills were administered each week.
Study: NCT04235686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mydayis Extended-Release Capsule
Description: Randomized, parallel - group, double-blind, placebo-controlled, flexible-dose adjunctive trial of MYDAYIS®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT02639663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental device
Description: Leboride~1. Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~   1. Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~  2. Control group: participants will not receive any device for breastfeeding pain control~2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental device
Description: Leboride~1. Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~   1. Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~  2. Control group: participants will not receive any device for breastfeeding pain control~2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
Study: NCT02623335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QPL (question prompt list) brochure
Description: The QPL intervention includes the QPL intervention brochure, plus a letter from the surgeon encouraging its use during the upcoming office visit. Intervention materials will be mailed in advance of the patient's appointment with an enrolled surgeon.
Study: NCT00090545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 43-9006
Description: 400 mg BAY 43-9006 orally twice daily in 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 43-9006
Description: 400 mg BAY 43-9006 orally twice daily in 28 day cycles.
Study: NCT03683394

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMARRT Intervention
Description: Interventionists will follow a standard protocol for delivering the SMARRT intervention that allows for personalization of the specific risk reduction action plan; these plans will evolve over time according to participant progress, motivation and preferences or newly identified risk factors. Staff will use a tracking database to record information for each participant, including session dates, identified risk factors, motivational barriers and important values, and the outcome of discussions around developing goals. For each participant, the exact number and mode (phone or in-person) of contacts will differ, but we will aim to have at least 1 contact per month with each participant. Best practice will include in-person meetings twice a year during the 2-year intervention period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Intervention
Description: Participants randomized to the Health Education (HE) group will receive mailed materials (typically 1-2 pages) every 3 months. This will include general information on Alzheimer's and dementia risk reduction using materials from sources such as the Alzheimer's Association and educational materials commonly provided as part of routine care at Kaiser Permanente Washington (KPWA).
Study: NCT01450982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 / MTX
Description: Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose
Study: NCT01681420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Counseling and Testing
Description: HIV counseling and testing in lieu of blood donation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Counseling and Testing
Description: HIV counseling and testing in lieu of blood donation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood Donation
Description: Blood donation without HIV counseling
Study: NCT03176082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailed Reminders with Fecal Immunochemical Testing kits

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reminder letter only
Study: NCT00063401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab:
Description: 400 mg/m2 loading dose, 250 mg/m2 weekly, six 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2 Day 1, six 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC = 6 Day1, six 21-day cycles